Summary & Overview
HCPCS Level II J9324: Injection, pemetrexed (Pemrydi RTU), 10 mg
HCPCS Level II code J9324 denotes the injectable chemotherapy agent pemetrexed (Pemrydi RTU) billed per 10 mg unit. Pemetrexed is a cytotoxic antifolate commonly used in the treatment of certain cancers, and precise coding at the unit level affects billing, inventory management, and clinical cost accounting for infusion services nationwide. Accurate use of J9324 is important for hospitals, outpatient infusion centers, and physician offices that provide chemotherapy.
Key payers included in this national overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what the code represents, the typical sites of service where it is used, and the context needed for claims submission. The publication summarizes how unit-based drug codes like J9324 factor into service lines involving chemotherapy, highlights common billing modifiers (listed separately), and outlines typical operational considerations such as dosing units and documentation requirements.
This analysis supplies benchmarks and policy-relevant context for payers and providers, describes potential areas for coding scrutiny, and presents clinical context to support accurate claim submission and reimbursement workflows. Data not available in the input are noted where applicable.
Billing Code Overview
HCPCS Level II code J9324 represents an injection of pemetrexed (Pemrydi RTU), 10 mg. This code is used to report administration of the chemotherapy agent pemetrexed supplied in a ready-to-use formulation and billed per 10 mg unit.
Service Type: Drug administration / Chemotherapy agent
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or physician office infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed advanced non-squamous non–small cell lung cancer (NSCLC) is scheduled to receive systemic chemotherapy including pemetrexed. The patient presents to the outpatient infusion center for intravenous administration of pemetrexed premixed in a ready-to-use formulation. Pre-infusion nursing assessment includes verification of identity, review of laboratory values (complete blood count, renal function), assessment for prior allergic reactions, and confirmation of folic acid and vitamin B12 supplementation status. The oncology pharmacist performs dose calculation based on body surface area, prepares the J9324 product in a sterile compounding area, and documents lot number and expiration. During the visit, an oncology nurse starts an infusion via peripheral IV or implanted port, monitors vital signs and infusion tolerance, and documents medication administration in the electronic health record. Typical sites of service are hospital outpatient infusion centers and freestanding oncology clinics. Expected modifiers may report drug wastage (JW), handling or storage circumstances, or patient status modifiers such as ambulatory surgical center (AS) when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |